1. Home
  2. RSKD vs OMER Comparison

RSKD vs OMER Comparison

Compare RSKD & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Riskified Ltd.

RSKD

Riskified Ltd.

HOLD

Current Price

$4.47

Market Cap

661.3M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$14.62

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSKD
OMER
Founded
2012
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
661.3M
772.8M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
RSKD
OMER
Price
$4.47
$14.62
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$5.96
$32.50
AVG Volume (30 Days)
663.3K
1.3M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$12.09
N/A
Revenue Next Year
$10.08
$233.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.70
$2.95
52 Week High
$5.68
$17.65

Technical Indicators

Market Signals
Indicator
RSKD
OMER
Relative Strength Index (RSI) 57.91 72.05
Support Level $4.42 $10.82
Resistance Level $4.85 $17.65
Average True Range (ATR) 0.15 0.68
MACD 0.03 0.26
Stochastic Oscillator 67.72 89.84

Price Performance

Historical Comparison
RSKD
OMER

About RSKD Riskified Ltd.

Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: